Centre allows SII to export 50 lakh Covishield doses under Covax
New Delhi: The Union government has allowed the Serum Institute of India to export 50 lakh doses of COVID-19 vaccine Covishield under the UN-backed COVAX global vaccine programme to Nepal, Tajikistan and Mozambique, official sources said on Sunday.
The SII will commence Covid vaccine export under the COVAX programme from November 23 and Nepal will receive the first lot of Covishield on November 24.
The government, earlier in October, had permitted the SII to export 10 lakh Covishield doses each to Nepal, Myanmar and Bangladesh under the 'Vaccine Maitri' programme.
In a recent communication to the Union Health Ministry, Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII) is learnt to have informed that the Pune-based firm has manufactured stock of 24,89,15,000 doses of Covishield and that the stock is increasing day by day.
Read also: Vaccine hesitancy big threat for India: SII
Serum Institute of India is an Indian biotechnology company headquartered in Pune. The company was founded in 1966 by Dr. Cyrus Poonawalla.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.